VitaSpring Biomedical Co. Ltd. (VSBC) stock
VSBCOTCServices-Commercial Physical & Biological ResearchFiscal year ends January 31
Số liệu tài chính tới Q2 năm tài chính 2027, quý kết thúc ngày Jul 31, 2026Last filing: 10-Q on Sep 17, 2026Score 4/30
$0.03+0.00 (0.00%)
Close on Oct 19, 2026Market cap $6.58MP/E –Yield –
VitaSpring Biomedical operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
VitaSpring Biomedical's operating cash flow for the twelve months ending Jul 31, 2026 was $10.57K. For fiscal 2026 it was -$2.69K. The highest annual figure on record is $401 in fiscal 2018.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Jan 31, 2026 | -$2.69K | – |
| FY2025 | Jan 31, 2025 | -$14.68K | – |
| FY2024 | Jan 31, 2024 | -$34.92K | – |
| FY2023 | Jan 31, 2023 | -$77.56K | – |
| FY2022 | Jan 31, 2022 | -$269.63K | – |
| FY2021 | Jan 31, 2021 | -$42.13K | – |
| FY2020 | Jan 31, 2020 | -$105 | – |
| FY2019 | Jan 31, 2019 | -$34.25K | -8640.6% |
| FY2018 | Jan 31, 2018 | $401 | – |
| FY2017 | Jan 31, 2017 | -$4.05K | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2027CQ2 2026 | Jul 31, 2026 | $5.20K | – |
| Q1 FY2027CQ1 2026 | Apr 30, 2026 | $6.08K | – |
| Q4 FY2026CQ4 2025 | Jan 31, 2026 | $124 | – |
| Q3 FY2026CQ3 2025 | Oct 31, 2025 | -$839 | – |
| Q2 FY2026CQ2 2025 | Jul 31, 2025 | -$1.19K | – |
| Q1 FY2026CQ1 2025 | Apr 30, 2025 | -$787 | – |
| Q4 FY2025CQ4 2024 | Jan 31, 2025 | -$1.79K | – |
| Q3 FY2025CQ3 2024 | Oct 31, 2024 | -$6.44K | – |
| Q2 FY2025CQ2 2024 | Jul 31, 2024 | -$2.42K | -1387.8% |
| Q1 FY2025CQ1 2024 | Apr 30, 2024 | -$4.02K | – |
| Q4 FY2024CQ4 2023 | Jan 31, 2024 | -$2.62K | -146.8% |
| Q3 FY2024CQ3 2023 | Oct 31, 2023 | -$4.55K | -284.8% |
| Q2 FY2024CQ2 2023 | Jul 31, 2023 | $188 | – |
| Q1 FY2024CQ1 2023 | Apr 30, 2023 | -$27.94K | – |
| Q4 FY2023CQ4 2022 | Jan 31, 2023 | $5.61K | – |
| Q3 FY2023CQ3 2022 | Oct 31, 2022 | $2.46K | -99.3% |
| Q2 FY2023CQ2 2022 | Jul 31, 2022 | -$57.56K | – |
| Q1 FY2023CQ1 2022 | Apr 30, 2022 | -$28.06K | -107.8% |
| Q4 FY2022CQ4 2021 | Jan 31, 2022 | -$27.98K | – |
| Q3 FY2022CQ3 2021 | Oct 31, 2021 | $376.80K | – |
| Q2 FY2022CQ2 2021 | Jul 31, 2021 | -$977.31K | – |
| Q1 FY2022CQ1 2021 | Apr 30, 2021 | $358.86K | +40085.8% |
| Q4 FY2021CQ4 2020 | Jan 31, 2021 | -$42.86K | – |
| Q3 FY2021CQ3 2020 | Oct 31, 2020 | $0 | – |
| Q2 FY2021CQ2 2020 | Jul 31, 2020 | -$165 | – |
| Q1 FY2021CQ1 2020 | Apr 30, 2020 | $893 | -41.1% |
| Q4 FY2020CQ4 2019 | Jan 31, 2020 | -$134 | -104.3% |
| Q3 FY2020CQ3 2019 | Oct 31, 2019 | -$284 | – |
| Q2 FY2020CQ2 2019 | Jul 31, 2019 | -$1.20K | – |
| Q1 FY2020CQ1 2019 | Apr 30, 2019 | $1.52K | – |
| Q4 FY2019CQ4 2018 | Jan 31, 2019 | $3.13K | -35.0% |
| Q3 FY2019CQ3 2018 | Oct 31, 2018 | -$19.79K | – |
| Q2 FY2019CQ2 2018 | Jul 31, 2018 | -$14.56K | – |
| Q1 FY2019CQ1 2018 | Apr 30, 2018 | -$3.03K | – |
| Q4 FY2018CQ4 2017 | Jan 31, 2018 | $4.82K | – |
| Q3 FY2018CQ3 2017 | Oct 31, 2017 | -$554 | – |
| Q2 FY2018CQ2 2017 | Jul 31, 2017 | -$1.60K | – |
| Q1 FY2018CQ1 2017 | Apr 30, 2017 | -$2.27K | – |
See a number that looks wrong?